Literature DB >> 34231298

The utility of genomic testing in the ophthalmology clinic: A review.

Kathryn P Burdon1.   

Abstract

Genomic testing assesses many genes in one test. It is often used in the diagnosis of heterogeneous single gene disorders where pathogenic variation in one of many genes are known to cause similar phenotypes, or where a clinical diagnosis is difficult to reach. In the ophthalmic setting, genomic testing can be used to diagnose several groups of diseases, including inherited retinal dystrophies, paediatric cataract, glaucoma and anterior segment dysgenesis and other syndromic developmental disorders with eye involvement. The testing can encompass several modalities ranging from whole genome sequencing to exome sequencing or targeted gene panels. The advantages to the patient of receiving a molecular diagnosis include an end to the diagnostic odyssey, determination of prognosis and clarification of treatment, access to accurate genetic counselling, and confirming eligibility for clinical trials or genetic specific therapies. Genomic testing is a powerful addition to the diagnosis and management of inherited eye disease.
© 2021 Royal Australian and New Zealand College of Ophthalmologists.

Entities:  

Keywords:  diagnostic techniques; genetics; genomics; inherited; sequencing

Year:  2021        PMID: 34231298     DOI: 10.1111/ceo.13970

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

1.  Commentary: Genomic testing is a powerful tool in diagnosing and managing anterior segment dysgenesis.

Authors:  Muralidhar Ramappa; Anshuman Verma; Deepak P Edward
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

2.  Multifaceted and Age-Dependent Phenotypes Associated With Biallelic PNPLA6 Gene Variants: Eight Novel Cases and Review of the Literature.

Authors:  Lorenzo Nanetti; Daniela Di Bella; Stefania Magri; Mario Fichera; Elisa Sarto; Anna Castaldo; Alessia Mongelli; Silvia Baratta; Silvia Fenu; Marco Moscatelli; Maria Teresa Bonati; Andrea Martinuzzi; Caterina Mariotti; Franco Taroni
Journal:  Front Neurol       Date:  2022-01-06       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.